Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 2/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17268188 | 0.89 | NFE2L2 (0.40) | GRM2NFE2L2HPGDGPR119MAOB | |
| SCHEMBL17260646 | 0.83 | NFE2L2 (0.44) | GRM2NFE2L2HPGDALDH1A1MAOB | |
| SCHEMBL17260648 | 0.83 | CA12 (0.49) | METHPGDALDH1A1MAPTNPSR1 | |
| SCHEMBL17260638 | 0.78 | RAB9A (0.51) | METHPGDALDH1A1MAPTNPSR1 | |
| SCHEMBL17260661 | 0.73 | HSD17B3 (0.46) | METHPGDALDH1A1MAPT | |
| SCHEMBL17260654 | 0.71 | MET (0.38) | METHPGDALDH1A1MAPTNPSR1 | |
| SCHEMBL17260660 | 0.67 | NFE2L2 (0.48) | GRM2NFE2L2HPGDMAPT | |
| SCHEMBL15864182 | 0.66 | MET (0.48) | METHPGDALDH1A1MAPTNPSR1 | |
| SCHEMBL17260683 | 0.65 | TP53 (0.53) | METHPGDALDH1A1MAPTNPSR1 | |
| SCHEMBL30674771 | 0.64 | NFE2L2 (0.70) | GRM2NFE2L2HPGDMAPTMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10226452-B2 | Benzoxazolone derivatives as acid ceramidase inhibitors, and their use as medicaments | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-03-12 | — | — | US | disclosed |
| US-10226452-B2 | Benzoxazolone derivatives as acid ceramidase inhibitors, and their use as medicaments | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-03-12 | — | — | US | disclosed |
| US-20170182010-A1 | BENZOXAZOLONE DERIVATIVES AS ACID CERAMIDASE INHIBITORS, AND THEIR USE AS MEDICAMENTS | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2017-06-29 | — | — | US | disclosed |
| US-20170182010-A1 | BENZOXAZOLONE DERIVATIVES AS ACID CERAMIDASE INHIBITORS, AND THEIR USE AS MEDICAMENTS | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2017-06-29 | — | — | US | disclosed |
| US-20170182010-A1 | BENZOXAZOLONE DERIVATIVES AS ACID CERAMIDASE INHIBITORS, AND THEIR USE AS MEDICAMENTS | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2017-06-29 | — | — | US | disclosed |
| WO-2015173168-A1 | BENZOXAZOLONE DERIVATIVES AS ACID CERAMIDASE INHIBITORS, AND THEIR USE AS MEDICAMENTS | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2015-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10226452-B2 | Benzoxazolone derivatives as acid ceramidase inhibitors, and their use as medicaments | ASAH1, ASAH2, ACER2 | MET 4852/4885GRM2 3488/4885NFE2L2 2226/4885 |
| US-20170182010-A1 | BENZOXAZOLONE DERIVATIVES AS ACID CERAMIDASE INHIBITORS, AND THEIR USE AS MEDICAMENTS | ASAH1, ASAH2, ACER2 | MET 4852/4885GRM2 3488/4885NFE2L2 2226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.